<!DOCTYPE html>
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>
<meta content="SAS 9.4" name="generator"/>
<title>SAS Output</title>
<style>
/*<![CDATA[*/
.body.c > table, .body.c > pre, .body.c div > table,
.body.c div > pre, .body.c > table, .body.c > pre,
.body.j > table, .body.j > pre, .body.j div > table,
.body.j div > pre, .body.j > table, .body.j > pre,
.body.c p.note, .body.c p.warning, .body.c p.error, .body.c p.fatal,
.body.j p.note, .body.j p.warning, .body.j p.error, .body.j p.fatal,
.body.c > table.layoutcontainer, .body.j > table.layoutcontainer { margin-left: auto; margin-right: auto }
.layoutregion.l table, .layoutregion.l pre, .layoutregion.l p.note,
.layoutregion.l p.warning, .layoutregion.l p.error, .layoutregion.l p.fatal { margin-left: 0 }
.layoutregion.c table, .layoutregion.c pre, .layoutregion.c p.note,
.layoutregion.c p.warning, .layoutregion.c p.error, .layoutregion.c p.fatal { margin-left: auto; margin-right: auto }
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r table, .layoutregion.r pre, .layoutregion.r p.note,
.layoutregion.r p.warning, .layoutregion.r p.error, .layoutregion.r p.fatal { margin-right: 0 }
article, aside, details, figcaption, figure, footer, header, hgroup, nav, section { display: block }
html{ font-size: 100% }
.body { margin: 1em; font-size: 13px; line-height: 1.231 }
sup { position: relative; vertical-align: baseline; bottom: 0.25em; font-size: 0.8em }
sub { position: relative; vertical-align: baseline; top: 0.25em; font-size: 0.8em }
ul, ol { margin: 1em 0; padding: 0 0 0 40px }
dd { margin: 0 0 0 40px }
nav ul, nav ol { list-style: none; list-style-image: none; margin: 0; padding: 0 }
img { border: 0; vertical-align: middle }
svg:not(:root) { overflow: hidden }
figure { margin: 0 }
table { border-collapse: collapse; border-spacing: 0 }
.layoutcontainer { border-collapse: separate; border-spacing: 0 }
p { margin-top: 0; text-align: left }
h1.heading1 { text-align: left }
h2.heading2 { text-align: left }
h3.heading3 { text-align: left }
h4.heading4 { text-align: left }
h5.heading5 { text-align: left }
h6.heading6 { text-align: left }
span { text-align: left }
table { margin-bottom: 1em }
td, th { text-align: left; padding: 3px 6px; vertical-align: top }
td[class$="fixed"], th[class$="fixed"] { white-space: pre }
section, article { padding-top: 1px; padding-bottom: 8px }
hr.pagebreak { height: 0px; border: 0; border-bottom: 1px solid #c0c0c0; margin: 1em 0 }
.stacked-value { text-align: left; display: block }
.stacked-cell > .stacked-value, td.data > td.data, th.data > td.data, th.data > th.data, td.data > th.data, th.header > th.header { border: 0 }
.stacked-cell > div.data { border-width: 0 }
.systitleandfootercontainer { white-space: nowrap; margin-bottom: 1em }
.systitleandfootercontainer > p { margin: 0 }
.systitleandfootercontainer > p > span { display: inline-block; width: 100%; white-space: normal }
.batch { display: table }
.toc { display: none }
.proc_note_group, .proc_title_group { margin-bottom: 1em }
p.proctitle { margin: 0 }
p.note, p.warning, p.error, p.fatal { display: table }
.notebanner, .warnbanner, .errorbanner, .fatalbanner,
.notecontent, .warncontent, .errorcontent, .fatalcontent { display: table-cell; padding: 0.5em }
.notebanner, .warnbanner, .errorbanner, .fatalbanner { padding-right: 0 }
.body > div > ol li { text-align: left }
.beforecaption > h4 { margin-top: 0; margin-bottom: 0 }
.c { text-align: center }
.r { text-align: right }
.l { text-align: left }
.j { text-align: justify }
.d { text-align: right }
.b { vertical-align: bottom }
.m { vertical-align: middle }
.t { vertical-align: top }
.accessiblecaption {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.aftercaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.batch > col, .batch > colgroup > col, .batch > colgroup, .batch > tr, .batch > * > tr, .batch > thead, .batch > tbody, .batch > tfoot { border: none; }
.batch {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: 'SAS Monospace', 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    padding: 7px;
    }
.beforecaption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.body {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    margin-left: 8px;
    margin-right: 8px;
}
.bodydate {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    text-align: right;
    vertical-align: top;
    width: 100%;
}
.bycontentfolder {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.byline {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.bylinecontainer > col, .bylinecontainer > colgroup > col, .bylinecontainer > colgroup, .bylinecontainer > tr, .bylinecontainer > * > tr, .bylinecontainer > thead, .bylinecontainer > tbody, .bylinecontainer > tfoot { border: none; }
.bylinecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.caption {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.cell, .container {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.contentfolder, .contentitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.contentproclabel, .contentprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.contents {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.contentsdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.contenttitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.continued {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    width: 100%;
}
.data {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.dataemphasis {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataemphasisfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.dataempty {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datafixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.datastrong {
    background-color: #ffffff;
    color: #000000;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.datastrongfixed {
    background-color: #ffffff;
    color: #000000;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.date {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.document, .errorbanner, .errorcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.errorcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.extendedpage {
    background-color: #ffffff;
    border-style: solid;
    border-width: 1pt;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
    text-align: center;
}
.fatalbanner, .fatalcontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.fatalcontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.folderaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footer {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.footerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.footerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.footerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.frame {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.graph > col, .graph > colgroup > col, .graph > colgroup, .graph > tr, .graph > * > tr, .graph > thead, .graph > tbody, .graph > tfoot { border: none; }
.graph {
    background-color: #ffffff;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.header {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headeremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headeremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.headerempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.headersandfooters, .headerstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.headerstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.index, .indexaction {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.indexitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.indexprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.indextitle, .linecontent, .list, .list10, .list2, .list3, .list4, .list5, .list6, .list7, .list8, .list9, .listitem, .listitem10, .listitem2, .listitem3, .listitem4, .listitem5, .listitem6, .listitem7, .listitem8, .listitem9, .note, .notebanner, .notecontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.notecontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.output > col, .output > colgroup > col, .output > colgroup, .output > tr, .output > * > tr, .output > thead, .output > tbody, .output > tfoot { border: none; }
.output {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.pageno {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
    text-align: right;
    vertical-align: top;
}
.pages {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
    margin-left: 8px;
    margin-right: 8px;
}
.pagesdate {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.pagesitem {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: none;
    margin-left: 6pt;
}
.pagesproclabel, .pagesprocname {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    list-style-type: decimal;
}
.pagestitle, .paragraph {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.parskip {
    background-color: #ffffff;
    border-spacing: 0;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.prepage, .proctitle {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.proctitlefixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooter {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooteremphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooteremphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowfooterempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowfooterstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowfooterstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheader {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderemphasis {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderemphasisfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: italic;
    font-weight: normal;
}
.rowheaderempty {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.rowheaderstrong {
    background-color: #6495ed;
    color: #ffffff;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.rowheaderstrongfixed {
    background-color: #6495ed;
    color: #ffffff;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: bold;
}
.systemfooter, .systemfooter10, .systemfooter2, .systemfooter3, .systemfooter4, .systemfooter5, .systemfooter6, .systemfooter7, .systemfooter8, .systemfooter9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: italic;
    font-weight: bold;
}
.systemtitle, .systemtitle10, .systemtitle2, .systemtitle3, .systemtitle4, .systemtitle5, .systemtitle6, .systemtitle7, .systemtitle8, .systemtitle9 {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: medium;
    font-style: normal;
    font-weight: bold;
}
.systitleandfootercontainer > col, .systitleandfootercontainer > colgroup > col, .systitleandfootercontainer > colgroup, .systitleandfootercontainer > tr, .systitleandfootercontainer > * > tr, .systitleandfootercontainer > thead, .systitleandfootercontainer > tbody, .systitleandfootercontainer > tfoot { border: none; }
.systitleandfootercontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.table > col, .table > colgroup > col, .table > colgroup, .table > tr, .table > * > tr, .table > thead, .table > tbody, .table > tfoot { border: none; }
.table {
    background-color: #cccccc;
    border-style: solid;
    border-collapse: separate;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    }
.titleandnotecontainer > col, .titleandnotecontainer > colgroup > col, .titleandnotecontainer > colgroup, .titleandnotecontainer > tr, .titleandnotecontainer > * > tr, .titleandnotecontainer > thead, .titleandnotecontainer > tbody, .titleandnotecontainer > tfoot { border: none; }
.titleandnotecontainer {
    background-color: #ffffff;
    border: none;
    border-spacing: 1px;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
    width: 100%;
}
.titlesandfooters, .usertext, .warnbanner, .warncontent {
    background-color: #ffffff;
    color: #003399;
    font-family: Arial, Helvetica, sans-serif;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
.warncontentfixed {
    background-color: #ffffff;
    color: #003399;
    font-family: 'Courier New', Courier, monospace;
    font-size: x-small;
    font-style: normal;
    font-weight: normal;
}
/*]]>*/
</style>
</head>
<body class="c body">
<div style="padding-bottom: 8px; padding-top: 1px">
<div id="IDX" class="systitleandfootercontainer" style="border-spacing: 1px">
<p><span class="c systemtitle">MR data set 2</span> </p>
</div>
<div style="padding-bottom: 8px; padding-top: 1px">
<table class="table" style="border-spacing: 1px" aria-label="Data Set REF.MR_SORTED_2">
<caption aria-label="Data Set REF.MR_SORTED_2"></caption>
<colgroup><col/><col/><col/></colgroup>
<thead>
<tr>
<th class="r header" scope="col">sub_ref_no</th>
<th class="header" scope="col">Title</th>
<th class="header" scope="col">Main_Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td class="r data">1</td>
<td class="data">High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease</td>
<td class="data">Our results add to the growing evidence that ApoB is the primary causal determinant for CAD risk among lipoprotein measurements. (8, 17, 18) XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Cholesterol underlies the development of atherosclerosis. (19) It enters the arterial wall within those ApoB-containing lipoprotein particles that are small enough to enter the tunica intima from the circulation; these particles include small VLDL, IDL and LDL particles as well as lipoprotein(a). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The recent genetic evidence, together with the results in this work, strongly point towards the direction that the lipid content of the particles is secondary to ApoB. (8, 18, 20) These results do not invalidate LDL-cholesterol as a causal risk factor for CAD risk. Indeed, LDL particles contain an apolipoprotein B molecule, as do IDL and VLDL particles. ApoB (in particular ApoB-100) represents the total number of hepatic-derived lipoprotein particles. (21) However, this investigation suggests that the clinical benefit of lowering triglyceride and LDL-C levels is proportional to the absolute change in ApoB. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ApoB measurements are independent of particle density, and are not affected by heterogeneity of particle cholesterol content. (22) This is particularly important for accurately capturing the number of small dense LDL particles, which are believed to be associated with atherosclerosis. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ApoB has been shown to be a superior measure to LDL-cholesterol in the prediction of CAD risk (23) and in prediction of coronary artery calcification. (24) From a clinical perspective, statins target LDL-cholesterol levels rather than ApoB, suggesting that greater benefit might be obtained from lipid-lowering drugs that target lipoprotein particle number. (25) XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When analysing data from UK Biobank only, there was also some evidence for triglyceride content measures as an additional risk factor. This was not evident in the main analysis or the sensitivity analysis including data from the earlier CARDIoGRAMplusC4D release. This finding should therefore be interpreted with some caution. There are some caveats to the interpretation of the results of this study. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although we were able to distinguish between measures of cholesterol content and triglyceride content for some categories of lipoprotein particles, we were not able to distinguish between other lipoprotein measures, such as cholesterol ester and phospholipid content, which correlated almost perfectly with cholesterol content. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
CONCLUSION =&gt; In conclusion, our agnostic investigation to identify risk factors for CAD strongly prioritized ApoB, suggesting that ApoB, representing the number of hepatic-derived lipoprotein particles, is the key determinant of CAD risk among
lipid-related measurements. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This analysis demonstrates the potential of publicly available genetic association data from high-throughput experiments combined with modern data-adaptive statistical learning techniques, for obtaining biological insights into disease aetiology. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">2</td>
<td class="data">Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization</td>
<td class="data">We here introduce MR-BMA, an approach for multivariable MR which allows for the analysis of high-throughput experiments. This model averaging procedure prioritises and selects causal risk factors in a Bayesian framework from a high-dimensional set of related candidate risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As is common for statistical techniques for variable selection, MR-BMA does not provide unbiased estimates. However, as shown in the simulation study, causal estimates from MR-BMA have reduced variance and thus MR-BMA improves over unbiased approaches, like the IVW method, in terms of mean squared error and detection of true risk factors.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The primary aim of this work is to detect causal risk factors rather than to unbiasedly estimate the magnitude of their causal effects. MR-BMA is a multivariable MR approach that can analyse a high-dimensional set of risk factors. XXXXXXXXXXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When analysing many risk factors jointly one important implicit assumption of MR-BMA is sparsity, i.e., the proportion of true causal risk factors compared with all risk factors considered is small. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Since MR-BMA evaluates all possible combinations of risk factors exhaustively or all relevant combinations of risk factors in a shotgun stochastic search there is an upper bound for the maximum model size in order to keep the computation tractable. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Sparsity is a common assumption for high-throughput data and we have seen in the applied example that the best models only contained one to three metabolites as risk factors despite allowing for a model size of up to twelve risk factors. Yet this is an important aspect of the algorithm and the maximum model size should be adjusted if models including many risk factors are expected or evidenced in the data. We demonstrated the approach with application to a dataset of NMR metabolites, which included predominantly lipid measurements, using variants associated with lipids as instrumental variables. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Previous MR analysis (23, 24) including three lipid measurements from the Global Lipids Genetics Consortium (19) have identified HDL cholesterol as potential risk factor for (age related macular degeneration) AMD. Our approach to multivariable MR refined this analysis and confirmed HDL cholesterol as a potential causal risk factor for AMD, further pinpointing that large or extra-large HDL particles are likely to be driving disease risk. Other areas of application where this method could be used include imaging measurements of the heart and coronary artery disease, body composition measures and type 2 diabetes, or blood cell traits and atherosclerosis. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As multivariable MR accounts for measured pleiotropy, this approach facilitates the selection of suitable genetic variants for causal analyses. In each case, it is likely that genetic predictors of the set of risk factors can be found, even though finding specific predictors of, for example, particular heart measurements from cardiac imaging, may be difficult given widespread pleiotropy (25). XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX MR-BMA allows a more agnostic and hypothesis-free approach to causal inference, allowing the data to identify the causal risk factors. Multivariable MR estimates the direct effect of a risk factor on the outcome and not the total effect as estimated in standard univariable MR. This is in analogy with multivariable regression where the regression coefficients represent the association of each variable with the outcome when all others are held constant. Having said this, the main goal of our approach is risk factor selection, and not the precise estimation of causal effects, since the variable selection procedure shrinks estimates towards the null. This results in causal effect estimates being biased towards the Null when there is a causal effect and unbiased estimates when there is no causal effect. If there are mediating effects between the risk factors, then this approach will identify the risk factor most proximal to and has the most direct effect on an outcome. For example, if the risk factors included would form a signalling cascade (Supplementary Fig. 1b) then our approach would identify the downstream risk factor in the cascade with the direct effect on the outcome and not the upstream risk factors in the beginning of the cascade. Hence, a risk factor may be a cause of the outcome, but if its causal effect is mediated via another risk factor included in the analysis, then it will not be selected in the multivariable MR approach. Our approach is formulated in a Bayesian framework. Particular care needs to be taken when choosing the hyper-parameter for the prior probability which relates to the a priori expected number of causal risk factors. In the applied example the results were robust to a wide range of prior specifications for the parameter as seen in Supplementary Table 10. In addition, the prior variance of the causal parameters needs to be specified and tested for robustness as we show in the Supplementary Table 11. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX When genetic variants are weak predictors for the risk factors, this can introduce weak instrument bias. In univariable two sample MR, any bias due to weak instruments is towards the null and does not lead to inflated type 1 error rates (26). However, in multivariable MR, weak instrument bias can be in any direction (see Methods), although bias will tend to zero as the sample size increases and consequently the instrument strength increases. Selection of risk factors is only possible if there are genetic variants that are predictors of these risk factors. One of the biggest challenges of multivariable MR is the design of a meaningful study, in particular the choice of both, the genetic variants and the risk factors. The design of the study is important for the interpretation of the risk factors prioritised: The ranking of risk factors is conditional on the genetic variants used. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For instance, in our applied example we find evidence for extra-large and large HDL cholesterol concentration given that we used lipid-related genetic variants as instrumental variables. We recommend to include only risk factors which have at least one, and ideally multiple genetic variants that act as strong instruments. Caution is needed for the interpretation of null findings, particularly in our example for non-lipid risk factors, as these might be deprioritised in terms of statistical power by our choice of genetic variants. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The instrument selection and general study design are essential for the MR-BMA approach and we strongly recommend the user to be critical in the choice of genetic variants and risk factors. Moreover, similar to standard MR we urge to perform model checks and be transparent in the presentation of the removal of outlier / influential genetic variants. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A further requirement for multivariable MR is that the genetic variants can distinguish between risk factors (12). We recommend to check the correlation structure between genetic associations for the selected genetic variants and to include no pair of risk factors which is extremely strongly correlated. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the applied example, we included only risk factors with an absolute correlation &lt;0.99. As we were not able to include more than three measurements for each lipoprotein category (cholesterol content, triglyceride content, diameter), care should be taken not to overinterpret findings in terms of the specific measurements included in the analysis rather than those correlated measures that were excluded from the analysis (such as phospholipid and cholesterol ester content). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Another assumption of multivariable MR is that there is no unmeasured horizontal pleiotropy. This means that the variants do not influence the outcome except via the measured risk factors. The assumption of no horizontal pleiotropy is a common and untestable assumption in MR. It is an active area of research to robustify MR against violations of this assumption. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Some of these robust methods for MR make a specific assumption about the behaviour of pleiotropic variants, such as MR-Egger (27), which assumes pleiotropic effects are uncorrelated from the genetic associations with the risk factor—the InSIDE assumption. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Other methods exclude outlying variants as they are potentially pleiotropic such as MR-PRESSO (28). XXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In multivariable MR, pleiotropic variants can be detected as outliers to the model fit. Here we quantify outliers using the q-statistic. Outlier detection in standard univariable MR can be performed by model averaging where different subsets of instruments are considered (29, 30), assuming that a majority of instruments is valid, but without prior knowledge which are the valid instruments. In multivariable MR, ideally one would like to perform model selection and outlier detection simultaneously. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, we search for genetic variants that are influential points. While these may not necessary be pleiotropic, we suggest removing such variants as a sensitivity analysis to judge whether the overall findings from the approach are dominated by a single variant. Findings are likely to be more reliable when they are evidenced by multiple genetic variants.  XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
CONCLUSION =&gt; In conclusion, we introduce here MR-BMA, the first approach to perform risk factor selection in multivariable MR, which can identify causal risk factors from a high-throughput experiment. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX MR-BMA can be used to determine which out of a set of related risk factors with common genetic predictors are the causal drivers of disease risk. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">3</td>
<td class="data">Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study</td>
<td class="data">The present MR study found evidence that genetic predisposition to higher plasma levels of ALA (alpha-linolenic acid), LA (linoleic acid), (palmitoleic acid) POA and  (Oleic acid) OA were associated with lower odds of type 2 diabetes, lower fasting glucose and higher HOMA-B score, whereas genetic predisposition to higher plasma levels of (eicosapentaenoic acid) EPA, (docosapentaenoic acid) DPA, (arachidonic acid) AA and (stearic acid) SA were associated with higher odds of type 2 diabetes, higher fasting glucose and lower HOMA-B score. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The associations except that for POA were driven by variants in FADS1/2, which explained the major proportion of variance in plasma fatty acid levels. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major limitation of this MR study is that SNPs in the FADS1/2 gene cluster were associated with most fatty acids and only three or fewer SNPs were available as instrumental variables for individual fatty acids, except for POA. This limited the possibility for disentangling the association of individual fatty acids with type 2 diabetes, and performing sensitivity analyses to explore pleiotropy. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The strong associations of FADS1/2 with fatty acid levels are not surprising because FADS1 and FADS2 encode Δ-5 desaturase and Δ-6 desaturase, respectively, which are key rate-limiting enzymes in the metabolism of fatty acids (Fig. 1). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Strong correlations between circulating biomarkers is not only an issue in the present MR study but can also be an issue in for example MR studies on metabolomics where several metabolites can be highly correlated. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our results are broadly in agreement with those of previous smaller studies of the associations of FADS1 and FADS2 genetic variants or Δ-5 and Δ-6 desaturase activities with type 2 diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A Chinese case–control study, including 331 individuals with type 2 diabetes and 421 healthy control individuals, found that the minor allele (T) of rs174616 in the FADS1-FADS2 gene cluster was associated with decreased AA/LA ratio and lower odds of type 2 diabetes [24]. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Results from a nested case-cohort study of 2653 German adults showed no overall association of rs174546, which is in complete linkage disequilibrium with rs174547, with type 2 diabetes [25]. However, that study revealed that a higher proportion of LA in erythrocytes and lower proportions of γ-linolenic acid and dihomo-γ-linolenic acid were associated with lower risk of type 2 diabetes. Furthermore, fatty acid ratios that reflect Δ5 desaturase and Δ-6 desaturase activity were respectively inversely and positively associated with type 2 diabetes [25]. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Similarly, results from a Finnish cohort study (407 overweight adults) [26] and an Iranian case–control study (95 individuals with type 2 diabetes and 95 without) [27] showed that Δ-5 desaturase activity was inversely associated with type 2 diabetes. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, a cross-sectional study of 576 Korean men showed that variants in the FADS gene cluster were associated with the proportions of LA, dihomo-γ-linolenic acid, and AA in serum phospholipids as well as with fasting insulin levels and HOMA-IR [28]. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Available data on the associations of circulating POA levels with the risk of type 2 diabetes and glycaemic traits are inconsistent [29–33]. Several population-based observational studies found that increased plasma or erythrocyte membrane POA level was associated with higher blood glucose levels [29], insulin resistance [30] and incidence of diabetes [31]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, in a prospective longitudinal study including 3630 Americans, circulating level of POA was not associated with the risk of diabetes and the positive association between POA level and insulin resistance was merely observed among men [30]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In addition, several studies concluded that increasing plasma POA level lowered fasting insulin, insulin resistance and the risk of type 2 diabetes [32]; this has been verified by cell experimental studies [33]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study, genetic evidence, excluding the influences from FADS and GCKR, supports a protective effect of increasing POA levels on fasting glucose level and type 2 diabetes. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Discrepancy between these findings may be attributable to residual confounding commonly affecting observational studies, such as type 2 diabetes-related nutrients, lifestyle determinants or endogenous sources introduced by dietary POA intake or de novo lipogenesis (e.g. key enzymes in fatty acid metabolism inflammatory factors and metabolic traits encoded by POA synthesis-related genes). XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX As for potential biological mechanisms, the associations of plasma fatty acid levels and genetic variations in FADS1/2 with type 2 diabetes may be mediated by impaired glucose tolerance and beta cell dysfunction, as suggested by the present MR study. It has been postulated that POA may prevent beta cell apoptosis induced by glucose or SFAs [34]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fatty acids are crucial structural components of cell membranes. The flexibility of a membrane, determined by the ratio of unsaturated to saturated fatty acyl chains of its phospholipids, influences the effectiveness of glucose transport via insulin-dependent glucose transporters [35]. A shift from unsaturated towards saturated fatty acyl chains of membrane phospholipids results in a decrease in glucose effectiveness and insulin sensitivity [36]. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Fatty acids are further precursors of eicosanoids, which may affect type 2 diabetes risk through inflammation [36, 37]. An experimental study in mice showed that loss of Δ-5 desaturase activity promoted hepatic inflammation and implied that endogenously synthesised AA and EPA are key determinants of inflammatory disease progression [38]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Associations of fatty acids with type 2 diabetes might also be explained by the effects of fatty acids on the gastrointestinal tract [37], intestinal microbiome [39] and nervous system [37]. XXXXXXX  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A further mechanism whereby fatty acids might affect the risk of type 2 diabetes is through blood cholesterol levels, which are inversely associated with risk of type 2 diabetes [40]. A meta-analysis of 60 trials revealed that SFAs increase total cholesterol and LDL-cholesterol levels, whereas MUFAs and PUFAs have the opposite effect, and that all types of fatty acid increase HDL-cholesterol levels [41]. The minor allele (C) of both rs174547 and rs102275 is associated with decreased levels of LDL-cholesterol, HDL-cholesterol and total cholesterol [42]. Thus, we would have expected a higher rather than lower odds of type 2 diabetes for the minor allele of rs174547 and rs102275 if the associations were mediated by cholesterol levels. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; This MR study showed that genetic predisposition to higher plasma ALA, LA, POA and OA levels and lower EPA, DPA, AA and SA levels was associated with lower odds of type 2 diabetes, lower fasting glucose levels and higher HOMA-B score. However, the causality for any individual fatty acid, except POA, cannot be inferred from this study due to the high correlation between the fatty acids. Notably, the observed associations, except that for POA, appeared to be driven by genetic variants in or close to FADS1/2.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">4</td>
<td class="data">Metabolomics insights into early type 2 diabetes pathogenesis and detection in individuals with normal fasting glucose</td>
<td class="data">We conducted a population-based prospective study in individuals with NFG at baseline, of whom 95 progressed to type 2 diabetes during the follow-up period of 20 years. Using information from a discrete set of 19 metabolites associated with type 2 diabetes incidence, we improved the capability of predicting incident type 2 diabetes beyond the predictions made using only the clinical risk factors obtained in routine care. XXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A significant biological finding is the enrichment in the nitrogen metabolism pathway with type 2 diabetes risk. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further, the genetic approach provides additional evidence that markers identified in the nitrogen metabolism pathway–glycine and phenylalanine–may be causal rather than only associative, suggesting that alterations in this pathway and its components may contribute to the earliest stages of type 2 diabetes pathogenesis. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX While prior clinical metabolomics studies have focussed on a mixture of individuals with normoglycaemia and prevalent dysglycaemia [10–18], our work is novel in its study of participants who were normoglycaemic yet progressed to type 2 diabetes. By studying individuals who progressed from having normal glucose metabolism to having type 2 diabetes, we eliminate confounding of our results by processes that occur in response to development of dysmetabolism (IFG or IGT). XXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The main clinical finding of the present study is that selected metabolites substantially improved the ability to predict type 2 diabetes, beyond the prediction achieved using conventional risk factors, in individuals classified as normoglycaemic based on fasting glucose. Our findings are slightly different from those of previous metabolomics studies, which were not able to show that metabolites materially improved type 2 diabetes risk prediction over other clinical risk factors [11, 15, 16]. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A possible explanation might be related to the study population: in normoglycaemic individuals, blood glucose and other traditional type 2 diabetes risk factors may not be as strong predictors of future type 2 diabetes as in those with dysglycaemia [30]. X XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Thus, novel risk factors like metabolites could show stronger predictive capability. Nevertheless, the AUC of clinical risk factors in normoglycaemic individuals was still &gt; 80%, slightly higher than reported in other recent studies [31, 32]. This suggests that differences in the length of follow-up or the inclusion of different ethnic groups could affect the predictive capability of traditional type 2 diabetes risk factors. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Another possible explanation for the increased predictive ability of metabolites might be related to the methodological approach implemented in this study. The predictive capability observed in this study is aligned with prediction performance observed in recent studies using similar machine learning approaches to prioritise metabolites [31, 32]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The normoglycaemic individuals included in this study were selected not only because of their normal fasting glucose but also because of their normal glucose tolerance and HbA1c, under current accepted definitions. Although different, perhaps more stringent, thresholds for ‘normal’ might have been chosen (especially as there were subtle elevations in fasting glucose among those who developed type 2 diabetes vs those who did not), we think that the data provide insight into early type 2 diabetes pathogenesis among those currently considered clinically normoglycaemic. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The convergence of selected metabolites in the nitrogen metabolism pathway, serving as nitrogen donors for the urea cycle [33], suggests that this pathway may influence the early pathogenesis of type 2 diabetes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data from the Mendelian randomisation experiments further support the notion that components within this pathway may have a causal role in type 2 diabetes development; therefore, confounding effects by obesity or lipid abnormalities are less likely. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In our study, genetically increased glycine reduced the odds of type 2 diabetes, consistent with findings from previous epidemiological studies in terms of directionality and effect sizes [15, 34]. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, this conflicts with a previous Mendelian randomisation analysis that showed no association between a single genetic variant for glycine or glycine-to-serine ratio and diabetes-related traits [35]. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX More precisely estimated effect sizes derived using data from the largest metabolites meta-genome-wide association studies currently available and the increase in the number of genetic variants used to proxy glycine here are likely to explain the difference between these two Mendelian randomisation studies. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX With regard to phenylalanine, different studies have reported a direct association between this metabolite and type 2 diabetes risk [11, 15, 34], although no Mendelian randomisation analysis for phenylalanine on type 2 diabetes risk has been conducted yet. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In the present study, we also documented that particular biomarkers previously associated with type 2 diabetes risk (e.g. TAGs with lower carbon number or 2-aminoadipate [12, 14]) are likely to be relevant even before initial glycaemic perturbations. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, other metabolites such as branched chain amino acids, associated with type 2 diabetes incidence in previous studies, were not prioritised by our selection algorithm. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Notably, our findings, which highlight early metabolite changes in the pathogenesis of type 2 diabetes, are consistent with a recent Mendelian randomisation analysis finding that elevations in branched chain amino acids occur after the development of insulin resistance [36]. We acknowledge that the results of our population-based analysis should be interpreted with caution since several limitations such as unmeasured factors (e.g. changes in lifestyle factors, medications or insulin secretion and resistance over time) might have influenced our findings. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Using a Mendelian randomisation approach for available metabolites in the nitrogen metabolism pathway partially mitigates this concern, suggesting that genetically driven glycine and phenylalanine are indeed related to the risk of type 2 diabetes independently of potential confounders. While our results were internally validated, we recognise that they were not confirmed in a separate prospective cohort. The lack of independent validation is due to the lack of availability of comparable cohorts of normoglycaemic individuals who developed type 2 diabetes for whom the necessary data were available. However, the internal validation approach, using 40% of the sample and running 100 iterations, allowed us to rule out other potential conflicting issues, such as compatibility between metabolomics platforms or available standards in libraries, even when similar platforms were used. XX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Five TAGs were prioritised by our methodological approach but we did not find significant enrichment of pathways associated with these species. This might be because the software we used for pathway enrichment analysis may provide poor reporting for lipid classes and pathways or because only five TAGs in a particular metabolic pathway are likely to be less than expected by chance for enrichment. In addition, most prioritised metabolites correlate with baseline clinical risk factors such as BMI, 2 h glucose, HOMA-IR, HDLc and TAGs (ESM Table 7) but associations of metabolites with type 2 diabetes in normoglycaemic individuals remained after risk factor adjustment. XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, we recognise that participants in this study were all of European descent. Further work is needed to determine whether our findings can be replicated in an independent cohort of the same ethnicity and to extend the study to other racial/ethnic groups. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; In conclusion, our study identifies a discrete set of metabolites that signal increased risk for type 2 diabetes among normoglycaemic individuals; these metabolites are involved and may play a causal role in the early stages of type 2 diabetes pathogenesis. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">5</td>
<td class="data">Effect of Insulin Resistance on Monounsaturated Fatty Acid Levels: A Multi-cohort Non-targeted Metabolomics and Mendelian Randomization Study</td>
<td class="data">bile acid, glycerophospholipid + caffeine metabolism associated with IR + FA biosynthesis =&gt; related to impaired insulin secretion XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Discovered + replicated causal effects of (insulin resistance) IR on lower levels of the mono-unsaturated (fatty acids) FAs (palmitoleic) POA + (Oleic Acid) OA + suggestive evidence for higher levels of aromatic amino acid tyrosine. Sensitivity analysis =&gt; no pleiotropic effects of the genetic instruments. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Causal effects =&gt; largely unaffected =&gt; exclusion of prevalent diabetes cases. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  All IR-increasing conditions =&gt; associated with down-regulation of SCD-1 (rate-limiting enzyme for mono-unsaturated FA biosysnthesis) =&gt; reduced endogenous prodn of OA + POA. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Palmitic + Stearic acid (saturated FAs) =&gt; SCD-1 Introduces double bonds =&gt; POA (16:1n-7) + OA (18:1n-9), respectively =&gt; major precursors cholesteryl esters + triglycerides (TGs) =&gt; packaged =&gt; very low density lipoprotein (VLDL) particles =&gt; secreted by the liver. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Reduced SCD-1 activity =&gt; adverse vascular outcomes: Inhibition of SCD-1 in hyperlipidaemic mice =&gt; increase aortic atherosclerosis despite protective effects on obesity + IR (37). Reduced SCD-1 activity =&gt; enrichment of saturated FA in VLDL + LDL =&gt; atherogensis =&gt; macrophage-induced vascular inflammation. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX   Competing effects on vascular + metabolic health. IR =&gt; reduces SCD-1 activity =&gt; counteracts the metabolic consequences of IR by improving insulin signalling BUT concomitantly =&gt; increases risk of CVD =&gt; saturated FA-induced proinflammatory changes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX IR +vely associated with OA (FDR-adjusted, p = 0.035, after adjustment for BMI pbmi &gt; 0.05) + POA levels (p = 0.091, pbmi &gt; 0.1) in contrast to -ve genetic associations in MR studies  XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Molecular mechns (1) =&gt; reduced tyrosine catabolism =&gt; IR-induced oxidative stress =&gt; elevations of methionine, cysteine + glutathione (antioxidant) =&gt; tyrosine hydroxylase inhibition (44). Molecular mechns (2) =&gt; inactivation of tyrosine aminotransferase XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Summary =&gt; multiple independent cohorts of community residents =&gt; causal effect of IR on circulating OA, POA + tyrosine levels =&gt; new insights into the metabolic signature of IR + impaired insulin secretion. 1st attempt =&gt; explore at large scale =&gt; causal effects of genetic IR =&gt; non-selected set of plasma metabolites. Potential implications =&gt; presumed IR-induced inhibition of monounsaturated FA biosynthesis =&gt; health outcomes =&gt; (require validation in experimental models) =&gt; form part of explanation for elevated CVD risk in IR that is independent of T2D development. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">6</td>
<td class="data">Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase</td>
<td class="data">Metabolomic profiling of statin use in longitudinal cohorts uncovered an intricate association pattern of circulating lipoprotein, fatty acid, and metabolite changes, which adds to our understanding of the LDL-C–independent effects of statins. Statin use was associated with pronounced lowering of numerous lipids and fatty acids consistent with the cardioprotective effects. By contrast, statin use did not markedly affect the circulating levels of recently identified biomarkers for cardiometabolic risk such as amino acids, glycolysis- and glycogenesis-related metabolites, or ketone bodies (5,6,21,31). The genetic proxy for HMGCR inhibition gave rise to a strikingly similar association pattern, providing unconfounded evidence that the observed metabolic changes arise as a consequence of the mechanism-based effect of statins (Central Illustration). XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These insights into an extensively studied therapeutic agent illustrate how metabolomics, combined with genetic proxies mimicking pharmacological action, can elucidate the molecular effects of known targets, clarify treatment indication, and potentially be used to inform drug development (19,20,34). XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Inhibition of HMGCR by statins leads to upregulated expression of LDL receptors in the liver, which in turn increases the uptake of circulating LDL particles. Using lipoprotein subclass profiling, statin therapy also was shown to be associated with considerable lowering of IDL and very small VLDL particle concentrations, beyond the anticipated decrease in LDL particles. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These remnant lipoprotein particles carry 20% to 30% of circulating cholesterol; they are small enough to enter the arterial intima and, therefore, possess the potential to cause atherosclerosis (14). Because total triglyceride concentration is highly correlated with the amount of IDL and small VLDL particles and their cholesterol levels, the triglyceride measure may partly reflect the cardiovascular risk mediated by the atherogenic remnant particles (14,15). XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Indeed, accumulating genetic evidence suggests that triglyceride levels reflect causal processes related to coronary heart disease (13–15); however, the likely underpinning mechanism is the remnant cholesterol carried in the IDL and VLDL particles (14,15,35). Detailed lipoprotein profiling demonstrated that statins are effective in lowering remnant cholesterol, whereas triglycerides are only modestly decreased by statin therapy. These results suggest that statins are substantially more efficacious for lowering remnant cholesterol than would be projected based on their ability to lower triglycerides. If the cardiovascular risk reflected by triglycerides is due to remnant cholesterol rather than triglycerides per se (14,35), then our results indicate cardioprotective benefits of statins beyond LDL-C lowering and suggest broader indications for statins in treating remnant hyperlipidemia. XXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The fatty acid composition of lipoprotein lipids vary greatly depending on the abundance of cholesteryl esters, triglycerides, and phospholipids (36). In accordance with linoleic acid being the primary constituent of cholesteryl esters—the dominant lipid in LDL particles—statin therapy led to the greatest lowering of this omega-6 fatty acid. Absolute levels of omega-3 fatty acids were only modestly decreased, in agreement with prior studies (12,37). These results are consistent with omega-3 fatty acids being primarily bound to the phospholipids, which only account for some 30% of the lipids in LDL particles (36). Monounsaturated and saturated fatty acids were decreased to a broadly similar extent as total triglycerides and phospholipids, respectively, which is coherent with the main fatty acid compositions for these lipid classes (36). The changes in the relative fatty acid balance due to statin therapy were modest. Although lower levels of the ratio of omega-6 fatty acids to total fatty acids have been associated with higher cardiovascular risk (5,38), evidence for a causal relation is lacking. The overall consistency between the genetic and longitudinal association patterns indicate that the various fatty acid modulations are on-target effects of HMGCR inhibition rather than due to cholesterol independent properties of statins (37). XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We also assessed whether statin therapy would be associated with biomarkers in various non-lipid
pathways. (Glycoprotein acetyl) GlycA, a measure of systemic inflammation and a biomarker for CVD and all-cause mortality (5,6,32,33,39), was modestly lowered, in accordance with the proposed anti-inflammatory properties of statins (7,8). XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX However, both longitudinal and genetic analyses provided no evidence for substantial effects of statins on amino acids, glycolysis and gluconeogenesis metabolites, and ketone bodies. Several metabolites in these pathways have recently been shown to be risk markers for CVD and type 2 diabetes (5,6,17,21,31). Although the potential causal roles of these biomarkers remain unclear, our results suggested that statin therapy would not be efficacious for lowering the cardiometabolic risk associated with these markers. XXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX CONCLUSIONS =&gt; High-throughput metabolomic profiling in large cohorts with multiple time points and genetic information elucidated the pharmacological effects of statins on lipoprotein subclasses including their lipid constituents and fatty acid composition. XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX These results suggest a more efficacious role of statins for lowering remnant cholesterol levels than would be expected based on the ability of statins to lower circulating triglycerides. XXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The absence of robust associations of statin use with circulating amino acids, glycolysis and gluconeogenesis metabolites, and ketone bodies suggest minimal pleiotropic effects on these non-lipid biomarkers. As a corollary, statin therapy appears to have little or no efficacy on these novel markers of cardiometabolic risk. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The exquisite match between the metabolic association patterns from observational and genetic analyses serves as a proof of concept, illustrating how the combination of metabolomics and genetic proxies for drug mechanisms can facilitate the assessment of pharmacological action and on-target effects for known therapies and novel drug targets. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Although Mendelian randomization of drug targets has been used previously (19,20,34), our study was
the first to our knowledge to combine the concept with observational results across a wide range of cardiometabolic biomarkers. As extensive metabolomics and genetic data are increasingly becoming available in large biobanks, such comprehensive molecular profiling can augment drug development in both preclinical and clinical trial stages to elucidate molecular mechanisms, clarify pleiotropic effects, and inform treatment indication. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
<tr>
<td class="r data">7</td>
<td class="data">Genetic markers as instrumental variables</td>
<td class="data">Economists have become increasingly interested in the effects of behaviours such as smoking, drinking or excessive food intake on economic outcomes. As these behaviours are endogenous and difficult (if not impossible) to randomize in an RCT, estimating their effects is difficult. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Many studies therefore attempt to find instrumental variables, or exploit some natural experiment that shifts the behaviour for some group, but not others, to identify their causal impact. The increasing availability of biomedical data, in combination with a growing medical literature on the effects of carrying specific genetic variants, introduces a different approach to the examination of certain risk factors on different outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This paper discusses the method of instrumental variables using Mendelian randomization, and links this to the statistical potential outcomes framework. Mendelian randomization provides a novel approach to estimating the causal impact, and with that will be of interest to economists to explore.

We note that its suitability and applicability depends on a set of (biological) conditions, as well as on the research question and context. We discuss the specific conditions that need to be met for genetic variants to be used as instruments, and relate these to the statistical assumptions necessary for identification of the average causal response using instrumental variables. These conditions have not been well defined in the current social science literature, but understanding them is crucial to the appropriate use of genotypes as instruments for modifiable risk factors.

We review these conditions in the context of two empirical applications. First, we examine whether child fat mass causally affects academic achievement, and second, we study whether it affects blood pressure. XXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX To study the effect of adiposity on our outcomes of interest, a well-conducted RCT would randomize an intervention that reduces fat mass and compare the outcomes between the group that was treated and the control group. Randomizing adiposity, however, is difficult. We show that, in such cases, quasi-experimental designs such as Mendelian randomization experiments can provide an interesting alternative approach. XXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX We use a set of 32 recently identified genetic variants as instrumental variables for fat mass to illustrate the key concepts. In these illustrative examples, we show the systematic approach required to identify genetic variants as instruments. We also use direct measures of fat mass, rather than the generally used BMI. OLS shows that leaner children perform better in school tests compared to their fatter counterparts, and that fatter children have higher blood pressure. Our genetic IV analysis, however, shows no evidence that children&apos;s fat mass affects their academic performance, whilst we find that fat mass increases children&apos;s blood pressure.

Our discussion of the conditions for the suitability of genetic variants as instrumental variables and our application raise some more general issues of the use of genetic variants as instruments. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX First is the question whether genetic variants are powerful enough to identify causal effects. In the illustrative case we examine, while our instruments are not weak in a statistical sense their effects may be too small to impact on the possible pathways to academic performance. In other words, a 1–2 kg increase in fat mass may not lead to a large drop in self-esteem or an increase in absenteeism. It is, therefore, perhaps not surprising that we find no significant effect on academic performance. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In contrast, our results on blood pressure show strong evidence of an increase driven by elevated fat mass. As intervention studies of weight reduction (see e.g. the meta-analysis of randomized controlled trials by Neter et al., 2003) have shown that a 5 kg weight loss is sufficient to cause a reduction in systolic blood pressure of about 4 mmHg, this suggests that even small changes in fat mass, such as those driven by genetic variants, can identify changes in blood pressure with sufficient precision (see also Timpson et al., 2009).

Hence, if small changes in the risk factor are sufficient to shift the outcome of interest, Mendelian randomization presents an interesting approach. However, if the outcome of interest is only affected by large changes in the risk factor, Mendelian randomization may not be sufficiently powerful, as genetic variants generally shift the risk factor by a relatively small amount. XXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This is particularly relevant for studies in economics, which are often interested in the effects of different intermediate phenotypes (e.g. adiposity, smoking, drinking) on economic outcomes. In contrast to various examples in the medical literature, finding effects on such economic outcomes generally requires larger changes in the risk factor. With most genetic variants having small effect sizes, this suggests they explain insufficient variation in the risk factor to affect the outcome of interest. With a rapidly growing medical literature on the effects of carrying specific variants, one option is to wait for more variants to be identified and to combine these into one a (weighted) count of the number of risk alleles. This could increase the explained phenotypic variation and with that, the precision of the estimates. But for the type of physical attributes that economists have been interested in such as fat mass or height, any additional variants are likely to have even smaller effects than those already identified (9).

A second issue is the credibility of the IV assumptions. Some of these are testable, but others are not. In particular, the validity of the exclusion restriction cannot be tested, and will never be known with certainty, which makes Mendelian randomization a controversial approach within the economics literature. XXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our paper has discussed this in detail and highlighted the various ways through which the use of genetic variants as instrumental variables may lead to invalid inferences. With our limited understanding of the functions of variants and the pathways through which they affect outcomes, it is unlikely that we will understand their exact function and mechanism in the foreseeable future. Hence, we argue that genetic variants need to be used with care. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Their appropriate use requires that several conditions, which have not hitherto been spelt out in the economics literature, are met. However, even if these conditions are met, the sample sizes in data sets that contain both genetic markers and outcomes of interest to economists may be too small to obtain definitive results. Indeed, even with around 4000–5000 observations, our standard errors are relatively large. But with a rapid increase in the number of genome wide association studies, and with a decrease in their costs, this may change. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Finally, just as there are good and poor RCTs and studies using any other identification design and methodology, there are good and poor Mendelian randomization studies. By highlighting the potential problems and showing the systematic approach required to identify genetic variants as instruments, we attempt to steer others to carefully consider the different assumptions and conditions needed for valid inference before jumping to their use. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX</td>
</tr>
</tbody>
</table>
</div>
</div>
</body>
</html>
